A global comparison of the cost of patented cancer drugs in relation to global differences in wealth

被引:88
作者
Goldstein, Daniel A. [1 ,2 ]
Clark, Jonathon [1 ]
Tu, Yifan [3 ]
Zhang, Jie [4 ]
Fang, Fenqi [4 ]
Goldstein, Robert [5 ]
Stemmer, Salomon M. [1 ,6 ]
Rosenbaum, Eli [1 ]
机构
[1] Rabin Med Ctr, Davidoff Canc Ctr, Petah Tiqwa, Israel
[2] Emory Univ, Winship Canc Inst, Atlanta, GA 30322 USA
[3] St Louis Univ Hosp, St Louis, MO USA
[4] Dalian Med Univ, Affiliated Hosp 1, Dalian, Peoples R China
[5] UCL, London, England
[6] Tel Aviv Univ, Sackler Fac Med, Tel Aviv, Israel
关键词
cost; affordability; METASTATIC COLORECTAL-CANCER; AMERICAN SOCIETY; BREAST-CANCER; CHEMOTHERAPY; BEVACIZUMAB; PERSPECTIVE;
D O I
10.18632/oncotarget.17742
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Introduction: There are major differences in cancer drug prices around the world. However, the patterns of affordability of these drugs are poorly understood. The objective of this study was to compare patterns of affordability of cancer drugs in Australia, China, India, Israel, South Africa, the United Kingdom, and the United States. Results: Cancer drug prices are highest in the United States. Cancer drugs are the least affordable in India by a large margin. Despite lower prices than in the USA, cancer drugs are less affordable in middle-income countries than in high-income countries. Materials and Methods: We obtained the prices of a basket of cancer drugs in all 7 countries, and converted the prices to US$ using both foreign exchange rates and purchasing power parity. We assessed international differences in wealth by collecting values for gross domestic product (GDP) per capita in addition to average salaries. We compared patterns of affordability of cancer drugs by dividing the drug prices by the markers of wealth. Conclusions: Cancer drugs are less affordable in middle-income countries than in high-income countries. Differential pricing may be an acceptable policy to ensure global affordability and access to highly active anti-cancer therapies.
引用
收藏
页码:71548 / 71555
页数:8
相关论文
共 18 条
[1]  
[Anonymous], 2015, World Economic Outlook Database, April, 2105
[2]   We all have AIDS: case for reducing the cost of HIV drugs to zero [J].
Berwick, D .
BRITISH MEDICAL JOURNAL, 2002, 324 (7331) :214-216
[3]   Cost-effectiveness of Early Treatment of Hepatitis C Virus Genotype 1 by Stage of Liver Fibrosis in a US Treatment-Naive Population [J].
Chahal, Harinder S. ;
Marseille, Elliot A. ;
Tice, Jeffrey A. ;
Pearson, Steve D. ;
Ollendorf, Daniel A. ;
Fox, Rena K. ;
Kahn, James G. .
JAMA INTERNAL MEDICINE, 2016, 176 (01) :65-73
[4]   A standardised, generic, validated approach to stratify the magnitude of clinical benefit that can be anticipated from anti-cancer therapies: the European Society for Medical Oncology Magnitude of Clinical Benefit Scale (ESMO-MCBS) [J].
Cherny, N. I. ;
Sullivan, R. ;
Dafni, U. ;
Kerst, J. M. ;
Sobrero, A. ;
Zielinski, C. ;
de Vries, E. G. E. ;
Piccart, M. J. .
ANNALS OF ONCOLOGY, 2015, 26 (08) :1547-1573
[5]   Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. [J].
Druker, BJ ;
Talpaz, M ;
Resta, DJ ;
Peng, B ;
Buchdunger, E ;
Ford, JM ;
Lydon, NB ;
Kantarjian, H ;
Capdeville, R ;
Ohno-Jones, S ;
Sawyers, CL .
NEW ENGLAND JOURNAL OF MEDICINE, 2001, 344 (14) :1031-1037
[6]   Cost-Effectiveness of Pertuzumab in Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer [J].
Durkee, Ben Y. ;
Qian, Yushen ;
Pollom, Erqi L. ;
King, Martin T. ;
Dudley, Sara A. ;
Shaffer, Jenny L. ;
Chang, Daniel T. ;
Gibbs, Iris C. ;
Goldhaber-Fiebert, Jeremy D. ;
Horst, Kathleen C. .
JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (09) :902-+
[7]   American Society of Clinical Oncology Perspective: Raising the Bar for Clinical Trials by Defining Clinically Meaningful Outcomes [J].
Ellis, Lee M. ;
Bernstein, David S. ;
Voest, Emile E. ;
Berlin, Jordan D. ;
Sargent, Daniel ;
Cortazar, Patricia ;
Garrett-Mayer, Elizabeth ;
Herbst, Roy S. ;
Lilenbaum, Rogerio C. ;
Sima, Camelia ;
Venook, Alan P. ;
Gonen, Mithat ;
Schilsky, Richard L. ;
Meropol, Neal J. ;
Schnipper, Lowell E. .
JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (12) :1277-+
[8]   First- and Second-Line Bevacizumab in Addition to Chemotherapy for Metastatic Colorectal Cancer: A United States-Based Cost-Effectiveness Analysis [J].
Goldstein, Daniel A. ;
Chen, Qiushi ;
Ayer, Turgay ;
Howard, David H. ;
Lipscomb, Joseph ;
El-Rayes, Bassel F. ;
Flowers, Christopher R. .
JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (10) :1112-1118
[9]   Pricing in the Market for Anticancer Drugs [J].
Howard, David H. ;
Bach, Peter B. ;
Berndt, Ernst R. ;
Conti, Rena M. .
JOURNAL OF ECONOMIC PERSPECTIVES, 2015, 29 (01) :139-162
[10]   Prices, Costs, and Affordability of New Medicines for Hepatitis C in 30 Countries: An Economic Analysis [J].
Iyengar, Swathi ;
Tay-Teo, Kiu ;
Vogler, Sabine ;
Beyer, Peter ;
Wiktor, Stefan ;
de Joncheere, Kees ;
Hill, Suzanne .
PLOS MEDICINE, 2016, 13 (05)